Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMiguel Sanmamed, MD, PhD
Assistant Professor AdjunctAbout
Research
Publications
2026
Phase 2b randomized, blinded, placebo-controlled trial to investigate the efficacy and safety of visugromab added to pembrolizumab, pemetrexed, and carboplatin in first-line metastatic non-squamous NSCLC: GDFATHER-NSCLC-01.
Reck M, Ferentinos K, Joerger M, Cobo M, Thiele B, D'Arcangelo M, Sanmamed M, Alexander M, Desai A, Gray J, Herbst R, Nieva J, Veluswamy R, Klar K, Fox M, Radulovic V, Lemke L, Leo E, Rao S, Lichtenegger F. Phase 2b randomized, blinded, placebo-controlled trial to investigate the efficacy and safety of visugromab added to pembrolizumab, pemetrexed, and carboplatin in first-line metastatic non-squamous NSCLC: GDFATHER-NSCLC-01. Journal Of Clinical Oncology 2026, 44: tps8665-tps8665. DOI: 10.1200/jco.2026.44.16_suppl.tps8665.Peer-Reviewed Original ResearchNon-squamous NSCLCImmune checkpoint inhibitorsPD-L1 tumor proportion scorePhase 2bImmune checkpoint inhibitor resistanceExploratory biomarker analysesPlacebo-controlled partStandard chemo-immunotherapyObjective response rateTumor proportion scoreProgression-free survivalGrowth differentiation factor 15Duration of responseRelapsed/refractory solid tumorsPlacebo-controlled trialDifferentiation factor 15Patient-reported outcomesCheckpoint inhibitorsExpansion doseChemo-ImmunotherapyDose escalationNeoadjuvant settingRECIST v1.1ECOG 0PD-L1Safety and feasibility of intratumoral injection of RP1 or RP2 oncolytic immunotherapies in visceral metastases.
Robert C, Bowles T, Middleton M, Michels J, Sanmamed M, VanderWalde A, Niu J, Gaudy-Marqueste C, Couselo E, In G, de Miguel M, Cervantes A, Beasley G, Liu T, Yanase K, Tucci C, Ulanet D, Hou J, Vanasse G, Milhem M. Safety and feasibility of intratumoral injection of RP1 or RP2 oncolytic immunotherapies in visceral metastases. Journal Of Clinical Oncology 2026, 44: 2597-2597. DOI: 10.1200/jco.2026.44.16_suppl.2597.Peer-Reviewed Original ResearchVisceral metastasesCombination therapyBleeding eventsAdverse eventsSafety dataTreatment-related adverse eventsVisceral tumorsAdvanced/metastatic solid tumorsLung injectionsNausea 1Data cutoffImmunotherapy platformIT injectionOncolytic immunotherapyLung biopsyChest tubeSafety profileSolid tumorsLiver injectionGM-CSFUltrasound guidanceMonotherapyClinical trialsCancer therapyMetastasisAnalysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial.
Gambardella V, Wermke M, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Luan J, Garcia-Alvarez A, Mishima S, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Capdevila J. Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial. Journal Of Clinical Oncology 2026, 44: 2642-2642. DOI: 10.1200/jco.2026.44.16_suppl.2642.Peer-Reviewed Original ResearchDelta-like ligand 3Primary tumor sitePhase I trialI trialTumor siteClinical developmentFirst-in-human phase I trialDiameter of target lesionsCohort of ptsDLL3-targeting therapiesExtrapulmonary neuroendocrine carcinomasLack of prospective dataAnti-PD-(L)1T-cell engagersPhase III developmentCharacteristics of patientsPD-(L)1Brain metastasesDLL3 expressionNeuroendocrine carcinomaMedian durationIII developmentTumor cellsTarget lesionsPrimary siteConventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
Lopez-Janeiro A, González-Gomariz J, Issa F, Hester J, Porciuncula A, Teijeira A, Luri-Rey C, Ruiz-Guillamon D, Perez-Gracia J, Perez-Ruiz E, Barragan I, Martín-Algarra S, Sanmamed M, Ortego I, Rodriguez-Ruiz M, Alexandru R, Rodriguez I, Arrieta-Aranzueque S, Rimm D, Aung T, Schalper K, de Andrea C, Melero I. Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer. Journal Of Clinical Investigation 2026, 136: e200987. PMID: 42065248, PMCID: PMC13132367, DOI: 10.1172/jci200987.Peer-Reviewed Original ResearchConceptsNon-small-cell lung cancerCD8+ T cellsCytotoxic T lymphocytesCheckpoint inhibitorsT cellsCD8+ T cell infiltrationConventional type 1 dendritic cellsContext of costimulatory moleculesType 1 dendritic cellsTissue immunofluorescenceCancer typesT lymphocyte densityCheckpoint inhibitor responseT cell infiltrationT cell activationT cell transcriptsAntigens to CD8Multiple cancer typesCostimulatory moleculesUrothelial cancerDendritic cellsFlt3-LCCL5 chemokinesClinical benefitT lymphocytesRadiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
Marco S, Fernández M, Honorato B, Juanarena N, Sainz C, Andueza A, Gould D, Anderson S, de Andrea C, Domínguez P, Wong P, Vásquez C, Narinda I, Unzu C, Isola S, Tavira B, Ariz M, Camps G, Sanmamed M, Pardo J, Labiano S, Alonso M, Marco-Sanz J, Guruceaga E, Collantes M, Simón J, Peñuelas I, Fernández-Irigoyen J, Santamaría E, Prieto J, Dubrot J. Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. Cancer Cell 2026, 44: 995-1011.e12. PMID: 41875889, DOI: 10.1016/j.ccell.2026.02.013.Peer-Reviewed Original ResearchAdeno-associated vectorsTumor microenvironmentImmunostimulatory tumor microenvironmentSystemic antitumor immunitySystemic antitumor responseCombination of RTImmune-evasion mechanismsInduce IL-12Antitumor immunityFas-dependent mannerAntitumor responseImmunotherapy platformTumor transductionIrradiated tumorsEpigenetic modificationsImmunostimulatory cytokinesImmunosuppressive factorsControl of transgene expressionIL-12RadiotherapyTransgene expressionLocal deliveryImmune systemConcomitant inductionTumorAn ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression. Endocrine Abstracts 2026 DOI: 10.1530/endoabs.116.c1.Peer-Reviewed Original ResearchReply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Arriola E, Wolf J, Villaruz L, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond. Journal Of Clinical Oncology 2026, 44: 1062-1064. PMID: 41570262, DOI: 10.1200/jco-25-02654.Commentaries, Editorials and LettersSafety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
Sanmamed M, de Andrea C, Ruiz-Guillamón D, Rodriguez-Ruiz M, Ortego I, Eguren-Santamaría I, Benito A, López-Janeiro A, Gonzalez Gomariz J, Villalba-Esparza M, Molina A, Krasko A, Ponz-Sarvise M, Lopez-Picazo J, Gomis G, Molero-Glez P, Alexandru R, Pérez-Domínguez P, Rodriguez I, Sánchez-Gregorio S, Perez-Gracia J, Melero I. Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab. Clinical Cancer Research 2026, 32: 1036-1045. PMID: 41543348, DOI: 10.1158/1078-0432.ccr-25-2502.Peer-Reviewed Original ResearchIntratumoral deliveryIntratumoral injectionAnti-CD137Associated with durable clinical benefitTumor-infiltrating CD8 T cellsPharmacodynamic activityPD-1/PD-L1 blockadeAgonistic anti-CD137Durable clinical benefitT lymphocyte densityDisease control rateDose-escalation cohortsT-cell-activating cytokinesCD8 T cellsFresh tumor biopsiesIntravenous nivolumabCD137 expressionTumor biopsiesSerial biopsyIntravenous dosePharmacodynamic changesPeripheral bloodClinical benefitT cellsSolid tumorsOrthotopic pleural mesothelioma mouse model
García R, Moreno D, Camps G, Vera L, Sanmamed M, Berraondo P, Aranda F. Orthotopic pleural mesothelioma mouse model. Methods In Cell Biology 2026 DOI: 10.1016/bs.mcb.2026.06.002.Peer-Reviewed Original ResearchSyngeneic mouse modelPleural mesotheliomaPleural cavityDisease progressionMurine mesothelioma cellsImmunocompetent C57BL/6 miceMalignant pleural mesotheliomaLocal tumor formationTumor burdenOrthotopic modelTumor microenvironmentPreclinical modelsC57BL/6 micePoor prognosisMesothelioma biologyAggressive cancerMesothelioma cellsTherapeutic strategiesTumor formationPleural spaceAsbestos exposureTherapeutic interventionsImmunological studiesTumorMesothelioma
2025
Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic
Eguren-Santamaria I, Melero I, Rodríguez I, Ortego I, Armero M, Galvez-Cancino F, López-Janeiro A, De Andrea C, Sanmamed M. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. Journal For ImmunoTherapy Of Cancer 2025, 13: e011279. PMID: 41161818, PMCID: PMC12574409, DOI: 10.1136/jitc-2024-011279.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHumanized mouse modelMouse modelImmunotherapy agentsClinical trialsHuman cancersFeatures of human cancersCancer immunotherapy applicationsPreclinical experimental modelsIn vivo modelsImmunotherapy interventionsPreclinical modelsPreclinical resultsClinical failureImmune cellsClinical developmentImmunotherapyImmunotherapy applicationsAnticancer treatmentHuman tumorsTherapeutic strategiesPreclinical researchEx vivoHuman specimensCancerExperimental model